# Naval University of Engineering

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/naval-university-of-engineering/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 49.8 |
| Citations | 299,093 |
| City | Wuhan |
| Country | CN |
| Description | Naval University of Engineering is a research organisation in Wuhan, CN. OpenAlex records 20,247 works and 299,093 citations for it. 6,686 researchers list it as their most recent affiliation. |
| Homepage | http://www.hjgcdx.cn/ |
| OpenAlex ID | https://openalex.org/I2800710378 |
| Researchers | 6,686 |
| ROR ID | https://ror.org/056vyez31 |
| Type | education |
| Wikidata ID | https://www.wikidata.org/wiki/Q10872997 |
| Works | 20,247 |

## University papers

Showing 12 of 57.

- [Osimertinib in Untreated <i>EGFR</i> -Mutated Advanced Non–Small-Cell Lung Cancer](https://scholariq.org/papers/osimertinib-in-untreated-i-egfr-i-mutated-advanced-non-small-cell-lung-cancer/)
- [Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer](https://scholariq.org/papers/pembrolizumab-plus-chemotherapy-for-squamous-non-small-cell-lung-cancer/)
- [Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial](https://scholariq.org/papers/pembrolizumab-versus-chemotherapy-for-previously-untreated-pd-l1-expressing/)
- [Overall Survival with Osimertinib in Untreated, <i>EGFR</i> -Mutated Advanced NSCLC](https://scholariq.org/papers/overall-survival-with-osimertinib-in-untreated-i-egfr-i-mutated-advanced-nsclc/)
- [Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial](https://scholariq.org/papers/dacomitinib-versus-gefitinib-as-first-line-treatment-for-patients-with-egfr/)
- [Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction](https://scholariq.org/papers/randomized-double-blind-placebo-controlled-phase-iii-trial-of-apatinib-in/)
- [Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)](https://scholariq.org/papers/updated-overall-survival-and-pd-l1-subgroup-analysis-of-patients-with-extensive/)
- [Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/regorafenib-plus-best-supportive-care-versus-placebo-plus-best-supportive-care/)
- [Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma](https://scholariq.org/papers/effect-of-camrelizumab-vs-placebo-added-to-chemotherapy-on-survival-and/)
- [First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study](https://scholariq.org/papers/first-line-erlotinib-versus-gemcitabine-cisplatin-in-patients-with-advanced-egfr/)
- [Osimertinib with or without Chemotherapy in <i>EGFR</i> -Mutated Advanced NSCLC](https://scholariq.org/papers/osimertinib-with-or-without-chemotherapy-in-i-egfr-i-mutated-advanced-nsclc/)
- [A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407](https://scholariq.org/papers/a-randomized-placebo-controlled-trial-of-pembrolizumab-plus-chemotherapy-in/)

## University researchers

- [Ying Cheng](https://scholariq.org/researchers/ying-cheng/)
- [Shiyan Sun](https://scholariq.org/researchers/shiyan-sun/)
- [Ze Wang](https://scholariq.org/researchers/ze-wang/)

## University top topics

Showing 8 of 21.

- [Advanced Sensor and Control Systems](https://scholariq.org/topics/advanced-sensor-and-control-systems/)
- [Advanced Algorithms and Applications](https://scholariq.org/topics/advanced-algorithms-and-applications/)
- [Advanced Measurement and Detection Methods](https://scholariq.org/topics/advanced-measurement-and-detection-methods/)
- [Underwater Acoustics Research](https://scholariq.org/topics/underwater-acoustics-research/)
- [Advanced Computational Techniques and Applications](https://scholariq.org/topics/advanced-computational-techniques-and-applications/)
- [Underwater Vehicles and Communication Systems](https://scholariq.org/topics/underwater-vehicles-and-communication-systems/)
- [Industrial Technology and Control Systems](https://scholariq.org/topics/industrial-technology-and-control-systems/)
- [Inertial Sensor and Navigation](https://scholariq.org/topics/inertial-sensor-and-navigation/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.